Table 3.
Change of co-prescribed medication during the three months before and after initiation with vericiguat
|
Prior to vericiguat initiation (n = 1416) |
After to vericiguat initiation (n = 1416) |
|
|---|---|---|
| HF co-medication | ||
| BB | 1113 (78.6%) | 1202 (84.9%) |
| ACEi | 236 (16.7%) | 204 (14.4%) |
| ARB | 179 (12.6%) | 168 (11.9%) |
| ARNi | 801 (56.6%) | 949 (67.0%) |
| Any RASi | 1113 (78.6%) | 1193 (84.3%) |
| MRA | 769 (54.3%) | 943 (66.6%) |
| SGLT2i | 724 (51.1%) | 1040 (73.4%) |
| Diuretic medication | 1124 (79.4%) | 1243 (87.8%) |
| Digitalis | 141 (10.0%) | 175 (12.4%) |
| Ivabradine | 82 (5.8%) | 104 (7.3%) |
| HF drug combinations | ||
| ≤ 1 drug class | 252 (17.8%) | 103 (7.3%) |
| 2 drug classes | 381 (26.9%) | 319 (22.5%) |
| 3 drug classes | 375 (26.5%) | 375 (26.5%) |
| 4 drug classes | 408 (28.8%) | 619 (43.7%) |
| Non-HF co-medication | ||
| Oral anticoagulant | 818 (57.8%) | 910 (64.3%) |
| Antiplatelet medication | 382 (27.0%) | 418 (29.5%) |
| Lipid-lowering medication | 881 (62.2%) | 960 (67.8%) |
| Glucose-lowering medication | 445 (31.4%) | 431 (30.4%) |
| Anti-depressant | 171 (12.1%) | 200 (14.1%) |
| NSAIDs | 177 (12.5%) | 157 (11.1%) |
| Antiobstructive medication | 346 (24.4%) | 349 (24.6%) |
| Gout medication | 414 (29.2%) | 436 (30.8%) |
HF heart failure, BB beta-blockers, MRA mineralocorticoid receptor antagonists, RASi renin–angiotensin system inhibitors, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ARNi angiotensin receptor–neprilysin inhibitor [ARNi]), SGLT2i sodium-glucose co-transporter-2 inhibitors, NSAIDs non-steroidal anti-inflammatory drugs